Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Repeat Doses of Serelaxin in Chronic Heart Failure
NCT01982292Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2014
- Primary completion
- Sep 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
A Phase 2 trial of serelaxin in chronic heart failure (CHF), sponsored by Novartis. Started May 2014; status: completed.
02
Drugs
serelaxin
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT01982292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01982292.